Volinanserin
Cat. No.：YN320935
CAS No. ：139290-65-6
| 产品名称: | Volinanserin |
| CAS No.: | 139290-65-6 |
| Chemical Name: | αR-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
| Synonyms: | MDL100907; M 100907 |
| 分子量: | 373.46 |
| 分子式: | C₂₂H₂₈FNO₃ |
| SMILES: | FC1=CC=C(CCN2CCC([C@@]([H])(O)C3=CC=CC(OC)=C3OC)CC2)C=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Volinanserin 是一种有效的，选择性的5-HT2受体拮抗剂，Ki值为 0.36 nM，对其选择性是对 5-HT1c，alpha-1 和 DA D2受体的 300 倍，可用于精神疾病的研究。 |
| IC50和靶点: | [{name:"5-HT2 Receptor:0.36 nM (Ki)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Sorensen, S.M., Kehne, J.H., Fadayel, G.M., et al.Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studiesJ. Pharmacol. Exp. Ther.266(2),684-691(1993)
Kehne, J.H., Baron, B.M., Carr, A.A., et al.Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profileJ. Pharmacol. Exp. Ther.277(2),968-981(1996)
Pehek, E.A., Nocjar, C., Roth, B.L., et al.Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortexNeuropsychopharmacology31(2),265-277(2006)
Ardayfio, P.A., Benvenga, M.J., Chaney, S.F., et al.The 5-hydroxytryptamine2A receptor antagonist R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the ratJ. Pharmacol. Exp. Ther.327(3),891-897(2008)
Boothman, L.J., Mitchell, S.N., and Sharp, T.Investigation of the SSRI augmentation properties of 5-HT2 receptor antagonists using in vivo microdialysisNeuropharmacology50(6),726-732(2006)
